SMC publishes Collaborative Advice Documents for remdesivir and tixagevimab plus cilgavimab for COVID-19
SMC has published Collaborative Advice Documents for remdesivir and tixagevimab plus cilgavimab for treating COVID-19. The recommendations are aligned with the NICE guidance for TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19.
Remdesivir (Veklury®) is accepted for restricted use in NHSScotland for treating COVID-19 in hospitals in specific patient groups.
Tixagevimab plus cilgavimab (Evusheld®) is not recommended for use in NHSScotland for the treatment of COVID-19 infection.
You can find the NICE final guidance here: Overview | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | Guidance | NICE
About us
- Who we are
- Horizon scanning
- Public involvement
- Policies & publications
- Minutes
- Meetings
- Register for a meeting
- ILAP
-
Latest update
- HIS website survey
- Speeding up access to new medicines in Scotland: abbreviated process
- International Collaboration
- Joint statement: NICE and SMC/HIS collaboration
- NICE draft recommendations published on the use of treatments for COVID-19
- Healthcare Improvement Scotland
- NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
- Her Majesty Queen Elizabeth II
- April 2022 decisions news release
- New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
- December 2021 decisions news release
- November 2021 decisions news release
- March 2023 decisions news release
- SMC publishes a Collaborative Advice Document for treatments for COVID-19
- Public Partner Advert
- Fast Track Resubmission Process
- NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
- SMC publishes an updated Collaborative Advice Document for COVID-19 medicines
- NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
- Contact us